Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.